SMi 4th Annual Conference – Lyophilization USA

November 15, 2018 - November 16, 2018

Event Navigation

Lyophilization is one of the most time-consuming and expensive operations, and improved drying technologies are required for current and future products. 16% of the top 100 pharmaceutical drugs and 35% of biologic drugs are lyophilized, and with more than 30% of the FDA-approved parenterals lyophilized and soon more than half of injectable drugs to require lyophilization, there’s a need for standardization and expansion of the lyophilization process in pharmaceuticals.

SMi’s Lyophilization USA conference will look toward the future of lyophilization. This years’ programme will help participants to discover novel techniques and advances within lyophilization; gain insight into the regulatory challenges in lyophilization and how to overcome these challenges; discuss the current unmet needs within lyophilization and action points needed to address these needs; explore the most recent analytical and other technologies in lyophilization; hear from experts on alternative freeze-drying methods beyond vial lyophilization making Lyophilization USA Conference the perfect platform to strengthen knowledge in key principles.

Organizer

Venue

Event Navigation

Pharma News HQ

Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.

Biohaven Pharmaceutical Holding Company, a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, has enrolled the first patient in a Phase 3 clinical trial assessing the efficacy [...]

To ensure you get the best experience on our website, we use cookies to analyze traffic and for ads measurements purposes including for serving Industry-based ads. By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.